Eurasian Pharmacopoeia Available

Recommendation
18-20 November 2025
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
The Eurasian Economic Commission published Volume 1 of the EAEU Pharmacopoeia. This Volume contains 157 general texts and general monographs. Individual monographs are expected to be published in Volume 2 which is currently being elaborated. The EAEU Pharmacopoeia is currently available in Russian language only.
The general texts and general monographs are to some extent harmonized with international Pharmacopoeias (e.g. European Pharmacopoeia, Ph. Eur.). However, there are still some important differences which might become challenging for globally operating companies. The EAEU Pharmacopoeia will come into force on 1st of March 2021.
Marketing authorization application dossiers on medicines for human use and medicines for veterinary use shall be brought into compliance with the requirements of EAEU Pharmacopoeia on 1st January 2026 at the latest.
Content of Volume 1 of the EAEU Pharmacopoeia
1. General Notices
1.1.General Statements
1.2. Other Provisions Applying to General Chapters and Monographs
1.3. General Texts and General Monographs
1.4. Individual Monographs
1.5. Abbreviations and Symbols
1.6. Units of the International System (SI) used in the Pharmacopoeia and Equivalence with other Units
2. General Chapters
2.1. Methods of Analysis
2.1.1. Apparatus
2.1.2. Physical and Physicochemical Methods
2.1.3. Identification
2.1.4. Limit Tests
2.1.5. Assays
2.1.6. Biological Tests
2.1.7. Pharmacognostic Tests
2.1.8. Methods used in Pharmacognostic Tests
2.1.9. Pharmaceutical Technical Procedures
2.2. Reagents
2.3. General Texts
2.3.1. General Texts on Microbiology
2.3.1.1. Efficacy of Antimicrobial Preservation
2.3.1.2. Microbiological Quality of Medicinal Products, and Active Substances (Active Pharmaceutical Ingredients, APIs) & Excipients for Pharmaceutical Use
2.3.1.3. Viral Safety
2.3.1.4. Microbiological Quality of Herbal Medicinal Products, and Herbal APIs & Extracts used in their preparation
2.3.2. Residual Solvents
2.3.3. Use of Alcoholimetric Tables
2.3.4. Polymorphism
2.3.5. Control of Impurities in Substances for Pharmaceutical Use
2.3.6. Characters Section in Individual Monographs
2.3.7. Functionality-related Characteristics of Excipients
2.3.8. Crystallinity
2.3.9. Dosage Form Tests
2.3.9.1. Recommendations for Dissolution Tests
Annex 4.1. Alcoholimetric Tables
Volume 1 of the EAEU Pharmacopoeia and Index are available at the EAEU website.
Related GMP News
17.09.2025When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
17.09.2025Dealing with Systems without Audit Trail Functionality
17.09.2025Why is RCA (Root Cause Analysis) so important?
10.09.2025The Use of Hoses in Pharmaceutical Production
10.09.2025Revision of EU-GMP Chapter 1 planned with Consultation Phase
10.09.2025Audit Trail Review by the QP / Dealing with a Lack of Justification